DM

Showing posts with label Testing. Show all posts
Showing posts with label Testing. Show all posts

Friday, June 28, 2013

Under-Use Of Genetic Testing Puts Health Of Entire Families At Risk

Main Category: Genetics
Also Included In: Cancer / Oncology;??Colorectal Cancer;??Breast Cancer
Article Date: 11 Jun 2013 - 0:00 PDT Current ratings for:
Under-Use Of Genetic Testing Puts Health Of Entire Families At Risk
not yet ratednot yet rated
A new study of the use of genetic testing for cancer-causing mutations in affected families in France has found that its take-up is very low. Professor Pascal Pujol, Head of the Cancer Genetics Department, Montpellier University Hospital, Montpellier, France told the annual conference of the European Society of Human Genetics that analysis of data from the French National Cancer Institute covering the years 2003 to 2011 showed that, although there had been a steady increase in tests performed for the breast and ovarian cancer-causing mutations BRCA1 and BRCA2, this was not the case with the MMR mutation, implicated in Lynch syndrome (a form of colorectal cancer). Only a third of relatives of individuals with either mutation underwent genetic testing themselves.

"Given that such testing can provide many options to enable individuals to manage their cancer risk, it is vital to encourage awareness and acceptance among both the public and medical professionals", he will say. "For example, removal of the ovaries in women over 40 years old who carry a BRCA mutation decreases their overall cancer mortality by 20% and prophylactic mastectomy can reduce the chances of breast cancer in women carrying such a mutation by around 90%. Those who are unwilling to undergo prophylactic surgery can benefit from increased surveillance, with regular MRI (magnetic resonance imaging) scans. For familial colon cancer, screening by colonoscopy has been shown to decrease mortality. It is therefore regrettable that so few people seem to be aware of the benefits of genetic testing in families with a history of breast, ovarian, or colorectal cancer."

Professor Pujol and colleagues from cancer centres across France analysed 240134 consultations and 134652 genetic tests from patients referred for a predisposition to breast or colorectal cancer. They found a substantial increase in tests for BRCA1/2 - from 2095 a year in 2003 to 7393 in 2011 - but for MMR mutations the increase was tiny - from 1144 to 1635 a year over the same period.

Mutations in BRCA1/2 genes are thought to be responsible for about 5% of all cases of breast and ovarian cancer. A woman with such a mutation has a risk of up to 87% of having breast cancer before she reaches the age of 80, as opposed to a risk of 8% in the general population. Such cancers are diagnosed at an average age of 43, as opposed to 60 in the general population, and are often more aggressive. In the case of ovarian cancer, a woman carrying a BRCA1 mutation has a risk of ovarian cancer of up to 63%.

Individuals with Lynch syndrome, or hereditary nonpolyposis colorectal cancer, have a 45% risk of developing colorectal cancer by the age of 70, and women with the syndrome are at increased risk of endometrial and ovarian cancers.

"While the increase in BRCA testing is encouraging, it is far from optimal. And the uptake of MMR testing for Lynch syndrome - responsible for 5% of all colorectal cancers - is frankly disappointing", says Professor Pujol. "And of course, positive test results may have implications for other family members.

"While we have only studied the situation in France, we believe that our findings would be likely to be replicated in many other countries across the world. It is extremely worrying that such a simple test, which has the potential to spare whole families from devastating illness, is being so under-used. We urgently need a major programme of awareness among all those concerned, involving medical education and training, information programmes for patients and their families, public health campaigning, and improved genetic counselling," he concluded.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our genetics section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

European Society of Human Genetics. "Under-Use Of Genetic Testing Puts Health Of Entire Families At Risk." Medical News Today. MediLexicon, Intl., 11 Jun. 2013. Web.
11 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Under-Use Of Genetic Testing Puts Health Of Entire Families At Risk'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Monday, June 17, 2013

Inostics' Blood-Based Mutation Testing Receives CLIA Certification

Main Category: Cancer / Oncology
Also Included In: Regulatory Affairs / Drug Approvals;??Blood / Hematology
Article Date: 04 Jun 2013 - 2:00 PDT Current ratings for:
Inostics' Blood-Based Mutation Testing Receives CLIA Certification
not yet ratednot yet rated
Inostics, a molecular diagnostics company that provides blood-based mutation testing, received CLIA (Clinical Laboratory Improvement Amendments) licensure for its clinical laboratory located in Baltimore, MD. This marks a critical milestone for the clinical adoption of this non-invasive molecular approach for the analysis of tumor biomarkers.

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making. We are extremely excited to be able to bring this solution to cancer patients as OncoBEAM tests offer a significant enhancement to clinical care over traditional tissue-based molecular testing," Dr. Frank Diehl, CSO of Inostics, said.

The OncoBEAM blood test is based on BEAMing technology which combines emulsion based digital PCR with flow cytometry. This technology enables the molecular analysis of tumor DNA shed from primary and metastatic tumors, found circulating in the blood of patients.

Due to its non-invasiveness, OncoBEAM blood tests introduce new possibilities for the management of various cancers like skin, colorectal, breast, and lung cancer. Now a simple blood draw can support clinical decision making in the context of therapy selection, assessment of drug response, resistance and recurrence monitoring, and detection of minimal residual disease (MRD).

Article adapted by Medical News Today from original press release. Source: Source: Inostics
Visit our cancer / oncology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Inostics. "Inostics' Blood-Based Mutation Testing Receives CLIA Certification." Medical News Today. MediLexicon, Intl., 4 Jun. 2013. Web.
5 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Inostics' Blood-Based Mutation Testing Receives CLIA Certification'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Saturday, May 18, 2013

More Sensitive Testing of Sentinel Nodes Does Not Appear Necessary

For breast cancer patients with a sentinel lymph node that appears free of cancer based on standard testing (hematoxylin-eosin staining), detection of very small areas of cancer in the lymph node through additional, more sensitive testing (immunohistochemistry) does not affect breast cancer outcomes. Standard testing of the sentinel node, therefore, appears to be sufficient. These results were published in the Journal of the American Medical Association.????

For women with early breast cancer, determining whether the cancer has spread to the axillary (under the arm) lymph nodes is an important part of cancer staging. Many women initially undergo a sentinel lymph node biopsy, in which only a small number of nodes (or even a single node) is removed. If the sentinel nodes show evidence of cancer, many women then undergo additional lymph node removal.??

In some cases, cancer in the lymph nodes may be too small to detect through standard procedures, but possible to detect through additional, very sensitive testing (immunohistochemistry). It’s been uncertain, however, whether use of immunohistochemistry to detect these very small areas of cancer provides a benefit.???

To explore the use of immunohistochemistry for the detection of very small areas of cancer in the sentinel node, researchers evaluated information from more than 5,100 women with early-stage breast cancer. Women were treated with breast-conserving surgery, sentinel lymph node biopsy, whole-breast radiation therapy, and (when appropriate) chemotherapy and/or hormonal therapy.??

Women whose sentinel nodes were cancer-free by conventional testing underwent additional testing with immunohistochemistry. Researchers also collected bone marrow samples in order to detect small areas of cancer in the bone.???

Of the sentinel nodes that tested negative (cancer-free) by conventional testing, 10.5% tested positive by immunohistochemistry. The very small areas of cancer detected only by immunohistochemistry, however, did not affect overall survival or the risk of cancer recurrence. ?Three percent of the bone marrow samples tested positive for cancer. Small areas of cancer in the bone marrow did appear to be linked with worse breast cancer outcomes, but the small number of affected women makes it difficult to draw firm conclusions. Also, collecting bone marrow samples is not routinely done.?

These results suggest that standard approaches to evaluating the sentinel lymph node appear to be sufficient. Very small areas of cancer in the lymph node that are missed by hematoxylin-eosin staining but detected by immunohistochemistry do not appear to affect breast cancer outcomes. ?

Small areas of cancer in the bone marrow may possibly predict worse breast cancer outcomes, but do not appear to be common enough in early breast cancer to warrant routine testing.?

Reference: Giuliano AE, Hawes D, Ballman KV et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. Journal of the American Medical Association. 2011;306:385-393.?

Posted November 3, 2011 (Updated from the August 1, 2011 article- Micrometastases in Sentinel Node Don’t Worsen Breast Cancer Survival)?


View the original article here